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ABSTRACT 
Objectives: To examine the longitudinal impact of the FDA’s Risk Evaluation and Mitigation 
Strategy (REMS) medication guide program on the contraindicated and non-contraindicated 
utilization of thiazolidenediones (TZDs) among Type 2 Diabetes Mellitus patients in Mississippi 
Medicaid. 
Methods: A retrospective quasi-experimental interrupted time-series design was conducted in 
MS Medicaid data for 2008-2012. TZD use in T2DM patients with and without prior heart 
failure diagnosis were defined as contraindicated and non-contraindicated use, respectively, and 
were the outcomes of interest. The date of the medication guide REMS introduction for 
rosiglitazone and pioglitazone were the primary interventions studied.  
Results: After adjusting for autoregressive and moving average trends in the data, a month-to-
month decrease for contraindicated and non-contraindicated use was observed prior to REMS 
and persisted following the REMS program for new and total contraindicated TZD use. REMS 
for rosiglitazone and pioglitazone did not result in a significant change in contraindicated TZD 
use. However, REMS for rosiglitazone resulted in a significant month-to-month decline in the 
overall and new non-contraindicated rosiglitazone (overall=-4.53, p<0.01; new=-64.61, p=0.02) 
and pioglitazone (overall=-7.58, p=0.01; new=-99.9, p=0.01) use.  
Conclusions: REMS programs, when preceded by safety warnings and media attention, may not 
only have a lasting impact on mitigating contraindicated utilization but may also have an effect 
on overall utilization, including non-contraindicated use. This implies that physicians, regulators 
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and insurance providers may act out of an abundance of caution and find alternatives to products 
with safety concerns rather than reconsider appropriate utilization patterns. 
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I. INTRODUCTION 
 
“Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable.” 
- Vladimir Lepakhin, (Assistant Director-General WHO), 20051  
 
 Regulation of pharmaceutical products over the past century has evolved to a system that 
is focused on ensuring that the benefits of drugs outweigh their risks. This change in focus is 
apparent from the growing role of the US Food and Drug Administration (FDA) as empowered 
by the Federal Food, Drug and Cosmetic Act and its many amendments. FDA policies in the 
latter part of 20th century were focused on pre-market safety assessments. However, pre-market 
clinical trials have been unable to identify rare and serious adverse drug reactions (ADRs) due to 
sample size constraints, controlled sample selection, or unsuitable safety measures.1 The need to 
identify ADRs is of grave concern due to their associated harmful health outcomes and high 
costs. A meta-analysis among hospitalized patients has found the incidence rate of ADRs to be 
6.7% between 1966 and 1996.2 In fact, in 1994 an estimated 2.2 million patients experienced 
serious ADRs resulting in 106,000 fatalities, thus making ADRs the fourth leading cause of 
death.2  The annual cost of ADRs, including both direct and indirect costs, was estimated, in 
1995, to be between $76 billion and $136 billion.3 Indeed, public outcries arising from the 
thalidomide, sulfanilamide, rofecoxib, and rosiglitazone safety events have fueled reforms in the 
regulation of pharmaceuticals to manage drug risks.4 
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The FDA has consequently endeavored to develop a more effective and efficient system 
to proactively identify and manage suspected ADRs. The availability of computerized data 
systems (e.g. administrative claims data, electronic medical records) together with the 
application of pharmacoepidemiology studies have permitted the expedient evaluation of safety 
signals indicating potential adverse events.4 The evidence generated may then be disseminated to 
health professionals and patients to prevent adverse events. Realizing the benefits, the Food and 
Drug Administration Amendments Act (FDAAA) of 2007 authorized the FDA to require 
manufacturers to implement and monitor Risk Evaluation and Mitigation Strategies (REMS). 
The purpose of REMS is to ensure appropriate drug utilization, such that therapeutic benefits 
outweigh any drug risks.5  
It is therefore prudent to examine whether REMS has the intended effect on drug 
utilization, such that inappropriate drug utilization is minimized with no residual effects on 
appropriate i.e. non-contraindicated drug utilization. This study will utilize a time-series 
approach to assess the effect of REMS on the utilization of thiazolidenediones (TZDs) among 
patients with cardiovascular disease. TZDs are prescribed for the treatment of Type 2 Diabetes 
Mellitus (T2DM) and are contraindicated in patients with cardiovascular disease. Beginning in 
2008, medication guides, the most common and least restrictive REMS, have been required by 
the FDA to promote and ensure appropriate TZD use.6 
 
Drug safety initiatives in the United States 
Pre-marketing focus  
Regulation of drug safety in the United States has largely been reactive to highly 
publicized safety events that were thought to be associated with the specific drug’s use. The 
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history of these initiatives is well described in the centennial edition of the FDA consumer 
magazine and  is summarized as follows.7 In 1906, the Pure Food and Drug Act was the first law 
that was enacted to protect consumers from the interstate transport of adulterated and misbranded 
drugs. The act was amended in 1912 to authorize the regulation of drugs with false claims of 
therapeutic effect. In response to the sulfanilamide disaster the Pure Food and Drug Act was 
replaced by the Federal Food and Drug Act of 1938; and this act authorized the FDA to review 
the safety of all drugs prior to market approval. In 1951, the Durham-Humphrey Amendment 
designated drugs as “prescription-only,” thus ensuring appropriate use under the supervision of a 
medical professional. In 1962, the Kefauver-Harris Amendment was urgently implemented in 
response to the thalidomide disaster. This amendment required manufacturers to conduct human 
trials to assess both safety and efficacy of the drug prior to seeking market approval. The FDA 
also began to monitor, inspect, and regulate drug labeling and drug manufacturing units. In fact, 
the 1962 amendment was the precursor to the current day drug regulatory environment. 
 
Post-marketing focus 
Despite a focus on drug safety, many instances of adverse events associated with drug 
use continued to be identified in the latter half of the 21st century. However, the FDA had limited 
capabilities to identify safety signals and consequently manage post-market drug evaluation. The 
FDA’s recourse to manage drug safety risks was through the use of patient package inserts and 
‘Dear Doctor’ letters. The recalls of Rezulin (troglitazone), in 2000, and the blockbuster drug, 
Vioxx (rofecoxib), in 2004, spurred further reforms that focused on post-marketing surveillance 
of drugs. In response to the criticism arising from the fallout of these recalls, the FDA issued 
guidelines for the development of Risk Minimization Action Plans (RiskMAPs).5 The FDA 
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required manufacturers to implement RiskMAPs to mitigate the adverse risks of their drugs. 
These RiskMAPs required the development of educational materials like medication guides to 
raise awareness of potential risks, and some RiskMAPs required a more restrictive drug 
distribution system.5 
In 2006, the Institute of Medicine (IOM) issued a report offering their recommendations 
regarding approaches to improve the risk assessment and surveillance of drugs in the U.S.8 In 
response to many of the findings from this report and the prevailing public health concern over 
drug safety issues, Congress passed the Food and Drug Administration Amendments Act 
(FDAAA) of 2007.  This act empowered the FDA to regulate and manage drug safety through 
the establishment of Risk Evaluation and Mitigation Strategies (REMS). The overarching goal 
was to ensure that drug benefits outweigh their risks. REMS appeared to be a formalized version 
of the FDA’s RiskMAP program. In fact, existing RiskMAP programs have since been converted 
to REMS.5 
 
Risk Evaluation and Mitigation Strategies (REMS) 
The FDA draft guidance5 describes REMS as a strategy to manage a serious risk that may 
be associated with a drug. If deemed necessary, the FDA may require a manufacturer to adopt a 
REMS program prior to drug approval (e.g. Onsolis®) to ensure that the benefits outweigh the 
risks. Alternatively, REMS may be required following drug approval, if and when new safety 
information indicates the need for REMS (e.g. Darvon®).5,9 Nonetheless, the industry may 
voluntarily undertake risk mitigation measures for a drug even if the FDA does not require 
REMS. Accordingly, supporting documents describing the proposed REMS must be submitted to 
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the FDA for approval. The FDA will then determine if any revisions need to be made prior to 
posting the approved REMS on their website.5 
The design of REMS may include elements such as medication guides, patient package 
inserts, communication plans, and Elements to Assure Safe Use (ETASU). Medication guides 
are meant to be included with the dispensed drug and are used to summarize FDA approved 
labeling (especially safety information). The purposes of communication plans are to inform 
healthcare professionals about the risks of the drug and the usefulness of a REMS program. 
ETASU are designed for drugs with a serious side-effects profile, and consequently limit the 
availability of the drug. REMS may include any or all components as deemed necessary by the 
FDA. 
All drug manufacturers that are subjected to REMS programs must provide frequent 
assessments regarding the effectiveness of REMS on mitigating identified risks. Additionally, an 
implementation system that specifies a mechanism for the administration of REMS may also be 
required. Any failure to comply with the approved REMS strategy renders the drug misbranded 
and the responsible manufacturer is subjected to monetary penalties.5  
Medication guides (MG):  Medication guides are FDA approved safety information 
guides that are required to be distributed when the agency determines that a drug poses a ‘serious 
and significant’ health risk.5 Circumstances that warrant a medication guide include (1) the 
expectation that it could help prevent serious risk; (2) when awareness of a serious drug risk 
could affect a patient’s decision to use the drug; or (3) when patient adherence to the guide is 
crucial to the drug’s effectiveness and patient health.5  
Communication plan (CP): The purpose of communication plans is to disseminate safety 
information and protocols to healthcare providers as may be necessary to mitigate drug risks. To 
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achieve this, manufacturers are expected to reach out to healthcare providers directly through 
letters or via professional organizations.5  
Elements to Assure Safe Use (ETASU): ETASU are the most restrictive element of 
REMS. They are required to ensure the safe use of effective drugs for which there exists 
evidence of serious risks.  For such drugs a medication guide or communication plan are judged 
to be insufficient to mitigate the risk. An ETASU may consist of any of the following elements 
that may limit availability of the drug: (1) Limiting prescribing to trained and certified healthcare 
providers who demonstrate an understanding of the risks and benefits of the drug and an ability 
to treat subsequent adverse events; (2) Limiting dispensing to pharmacies, practitioners, or 
facilities who are trained and certified in the management of the drug under conditions that 
assure their safe use; (3) Administering the drug in health settings that are certified to be capable 
of managing adverse events; (4) Limiting prescribing to clinically appropriate patients who 
demonstrate and acknowledge an understanding of the risks and benefits of the drug; (5) 
Requiring that each patient enroll in a registry that permits the monitoring of their condition, 
therapy, and outcomes.5  
 
REMS assessment 
 All REMS are required to be evaluated at regular intervals to assess the extent to which 
its goals are being met and to accordingly determine whether any modifications are required to 
be made. A timetable identifying these dates must be submitted to the FDA along with the 
REMS program for approval. Assessments are required to be submitted 18 months, 3 years, and 
7 years following REMS approval. Assessment studies may include patient surveys or 
administrative claims data to evaluate changes in drug utilization or adverse events. Claims-
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based analysis and survey methods are examples of methods that may be used for collecting and 
analyzing REMS effectiveness.5 Further, a threshold value of the outcome measure at which 
appropriate REMS modifications are justified should also be set. As an example, the FDA 
suggests that a survey be used to assess patient awareness of serious adverse events.5 Other 
outcomes that may be assessed include the extent to which medication guides as REMS are 
appropriately distributed. Additionally, the change in rates of adverse events or utilization among 
contraindicated patient groups is a useful and important outcome. 
 
Description of FDA-approved REMS 
The FDAAA as passed in 2007 empowered the FDA to begin approving REMS by 2008. 
A descriptive analysis of approved REMS published on the FDA website reveals that by April 
2011, the FDA had approved and published REMS for 180 drugs or drug classes.9 In 2008, 
REMS were approved for 25 drugs. In 2009, the FDA approved REMS for 75 drugs and updated 
existing REMS for seven drugs. In 2010, REMS were approved for 63 drugs and existing REMS 
for 39 drugs were updated. From January to April of 2011, the FDA approved REMS for 19 
drugs and updated the REMS for 23 drugs. 
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Figure I: FDA approved REMS by year 
 
 
All approved REMS, with the exception of three, have required a medication guide. 
Specifically, 119 REMS were approved with medication guides only, 38 were approved with a 
medication guide and communication plan, six require a medication guide, communication plan, 
and ETASU, 14 require a medication guide and ETASU, one requires a communication plan 
only, and two have been approved with a communication plan and ETASU.  Therefore, 
cumulatively 98% of all approved REMS require medication guides, 26% require 
communication plans, and 12% require ETASU. 
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Figure II: FDA approved REMS by type 
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and Duetact®). These TZDs were first approved by the FDA in 1999 (troglitazone was 
withdrawn in 2000).  
119
38 14 6 2 1
66%
21%
8%
3% 1% 1%
0%
10%
20%
30%
40%
50%
60%
70%
0
20
40
60
80
100
120
140
MG only MG + CP MG +
ETASU
MG + CP +
ETASU
CP +
ETASU
CP only
9 
 
As per consensus guidelines developed by the American Diabetes Association and the 
European Association for the Study of Diabetes, TZDs are considered to be a second-line 
therapy to lifestyle modification and metformin for T2DM.11 TZDs act as “insulin sensitizers” to 
lower blood glucose levels and have demonstrated a 0.5-1.4% decrease in A1c levels when used 
as monotherapy.11 Edema due to increase in fluid retention and weight gain have been identified 
as side-effects of TZD use.11 Early clinical trials, at the time of and soon after FDA approval for 
TZDs, signaled possible cardiovascular risks among rosglitazone users.12 However, these trials 
were not designed or powered to examine such rare risks. It has been suggested that there might 
be a link between edema and heart failure (HF) from TZD use.13,14  
In May 2007, a meta-analysis found evidence that rosiglitazone was associated with a 
significant increase in myocardial infarction (MI). In response to these findings, the FDA 
immediately issued a safety alert warning about the potential cardiovascular risks of TZDs.15 
Subsequently, an FDA advisory committee was convened to discuss the issue. This committee, 
while acknowledging the risk, decided that the benefits of rosiglitazone favored its availability in 
the market.16 The committee also noted that clinical trial data offered inadequate evidence 
regarding the risk of rosiglitazone. However, the committee suggested that adverse 
cardiovascular events associated with TZDs appeared to become exacerbated among patients 
with prior HF.16 Consequently, a black box warning was added to rosiglitazone and pioglitazone 
labels in August 2007 cautioning about the increased risk of HF. In November 2007 the label for 
rosiglitazone was updated with a safety warning about the possible but inconclusive risk of MI.16 
 In February 2008, in accordance with RiskMAP guidelines the FDA required medication 
guides be distributed to patients to inform them about the risks of taking Avandia®.17 Following 
the approval of FDAAA 2007, REMS medication guides were required for TZDs, which were 
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then extended to Avandaryl® and Avandamet® in December, 2008, and to Actos®, Actoplus 
Met®, and Duetact® in September, 2009.9   
  
Objectives and justification 
The effect of the safety warnings and media coverage regarding the adverse 
cardiovascular events associated with TZDs on their utilization has previously been studied.18-20 
However, REMS is a relatively newer program and consequently its effect on drug utilization 
has not been examined in the academic literature. Manufacturers of drugs for which REMS were 
approved in 2008, as per the FDA required REMS assessment timetable, would not have 
submitted initial assessments of REMS effectiveness until 2010. Therefore, an examination of 
the effectiveness of REMS is timely. 
The adverse cardiac effects associated with TZDs have received much safety, regulatory, 
and media attention. The TZD class of drugs had blockbuster sales before FDA safety warnings 
were first issued in 2007 regarding their cardiac effects. Total sales in 2006 amounted to $3.3 
billion for rosiglitazone and $2.8 billion for pioglitazone.12 Therefore, an examination of TZD 
utilization is of special interest. 
There is a paucity of research that examines the effect of safety warnings and risk 
mitigation strategies on contraindicated drug utilization. TZDs are contraindicated in patients 
with a history of cardiovascular disease. It has been reported that contraindicated use of 
rosiglitazone continued to be high following the FDA’s safety warning in 2007 and prior to 
REMS. In fact, about a third of all TZD use among T2DM patients have been found to 
contraindicated. 20   Therefore, it would be most useful to test the efficiency of TZD REMS on 
decreasing contraindicated utilization among T2DM patients with cardiovascular disease.   
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Medication guides are the most common REMS element. It is intended to communicate 
risk information to patients but does not offer safeguards to assure that contraindicated use is 
avoided, as may be available in an REMS program with ETASU. Therefore, an examination of 
the effect of medication guides as REMS on the contraindicated drug utilization is of significant 
importance. Beginning in 2011, the FDA requires a restricted access program be put in place for 
Avandia® to limit its use and mitigate the risks for adverse cardiovascular events. 
For these reasons the objectives of this study are to examine the effect of FDA approved 
medication guides REMS for TZDs on their contraindicated drug utilization patterns among 
T2DM patients. To evaluate the objectives a time series analysis of Mississippi Medicaid data 
will be conducted to assess the change in (a) new and total contraindicated use and (b) new and 
total non-contraindicated use among T2DM beneficiaries.  
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II. LITERATURE REVIEW 
 
Thiazolidinediones for Type 2 Diabetes Mellitus and cardiovascular disease 
 Diabetes has been recognized as a predictor of cardiovascular disease. The American 
Diabetes Association reports that 68% of diabetes related deaths in 2004 were from 
cardiovascular causes.21  Diabetes, in fact, has been reported to double, and in some cases 
quadrupule, the risk of cardiovascular.21 Nearly half of all myocardial infarctions have been 
found to occur among patients suffering from diabetes.22 The susceptibility of diabetic patients to 
comorbid illnesses, especially cardiovascular disease, has given rise to public health concerns 
regarding the exacerbation of such conditions from diabetes therapy. A case in point is the 
concern of HF among T2DM patients taking TZDs. 
In 1999, the U.S. FDA approved rosiglitazone for the treatment of T2DM due to its 
demonstrable ability to reduce blood glucose levels.23 The drug had a novel mechanism of action 
i.e. insulin sensitization, whereby it increased the utilization of insulin in hepatic and peripheral 
tissues.13 On account of this action TZDs are especially useful in treating patients who are insulin 
resistant. TZDs are considered to be only slightly less effective than meformin and sulfonylureas 
in the management of hyperglycemia.24 In placebo-controlled randomized clinical trials TZDs 
demonstrated about one and a half percentage point decrease in A1c levels, thus, effectively 
decreasing levels in a typical T2DM patient from 8.5% to 7%.13,24 In comparison, the normal 
glycosylated hemoglobin range is between 4% and 6% among non-diabetics.13  
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However, the use of TZDs has been found to be associated with weight gain and 
peripheral edema, due to fluid retention. It has been reported that for every percent decrease in 
A1c values, TZDs may result in a 2 to 3 kilogram weight gain due to subcutaneous fat deposition 
or edema.13 Consequently, it is reasoned that the weight gain and edema may be the cause of the 
higher incidence of HF observed among TZD users.13 
Several studies have examined the risk of cardiovascular disease among users of TZDs. 
Among these are prospective clinical trials designed to evaluate cardiovascular outcomes, meta-
analyses of randomized trials designed to evaluate hypoglycemic outcomes, and observational 
studies. The American Heart Association and the American College of Cardiology Foundation 
published a scientific advisory in 2010 following a systematic review of most studies that have 
examined the effect of TZDs on cardiovascular outcomes.25 Based upon the review, it was 
concluded that there is a risk of cardiovascular disease associated with TZD use. The report 
cautioned against the use of TZDs among patients with a history of HF.  
 
Rosiglitazone and cardiovascular risk: Controlled studies (vs. placebo or oral hypoglycemics) 
Clinical trials 
 In 2007, Nissen and Wolski published a widely publicized meta-analysis to determine 
whether rosiglitazone use was associated with adverse cardiovascular events and death.26 For the 
study they analyzed data from 42 randomized clinical trials having a study duration of at least 24 
weeks. They found that patients exposed to rosiglitazone had a significantly higher risk of 
myocardial infarction (MI) as compared to controls. The meta-analyses revealed that patients on 
rosiglitazone had a 43% higher odds of MI events (OR = 1.43, 95% CI = 1.03-1.98). Almost 
immediately in response to this evidence the FDA issued a safety warning regarding the 
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cardiovascular effects of TZD.15 To corroborate these findings, GlaxoSmithKline- the 
manufacturers of Avandia and the FDA each conducted independent meta-analysis of the RCT 
data for rosiglitazone. Limiting their analysis to double-blinded trial studies of T2DM patients, 
both studies found a significant but smaller risk of ischemic heart disease (IHD) but no risk of 
cardiovascular-related death. GlaxoSmithKline reported a 31 % higher risk for IHD (HR = 1.31, 
95% CI = 1.01-1.70) 27 and the FDA found a 39% higher odds of IHD (OR = 1.39, 95% CI = 
1.10-1.80). 28 These findings prompted the FDA to modify the boxed warning for rosiglitazone 
to specify that the use of TZDs in patients with preexisting HF may increase the risk of adverse 
cardiovascular outcomes. Psaty and Furberg augmented Nissen and Wolski’s analysis with data 
from the “Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in 
Diabetes trial” (RECORD).29  RECORD is a large prospective randomized controlled 
multicenter trial designed to examine cardiovascular outcomes among rosiglitazone users. They 
found that rosiglitazone users had a 33% higher odds (OR = 1.33, 95% CI = 1.02-1.72) of MI. 
Singh, Loke, and Furberg also found a statistically higher risk of MI among TZD users.30 
However, none of the aforementioned studies found a statistically significant risk for death due 
to cardiovascular events.26-30  
Contrary to much evidence suggesting a high risk for adverse cardiovascular outcomes, 
some studies have failed to find any significant effects. A review of 18 double-blinded trials by 
the Cochrane Library did not find rosiglitazone to be associated with a higher risk for MI 
events.31 Additionally, the RECORD trial did not find a significant risk of hospitalization or 
death from cardiovascular events (HR = 1.08, 95% CI = 0.89-1.31). 32 However, the study did 
find that that patients with HF were significantly more likely to be in the rosiglitazone study arm 
(HR = 2.15, 95% CI = 1.30-3.57). The results of the RECORD trial are limited in their 
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applicability due to the low observed event rates which precludes an appropriately powered 
analysis, suboptimal medication adherence that was observed, and the concurrent use statins that 
appeared to benefit rosiglitazone users. Nonetheless, the findings validate the results of another 
meta-analysis by Lago, Singh, and Nesto, which demonstrated that despite a two-fold increase in 
the risk for HF among rosiglitazone users there was no increase in mortality.33 
Updated results of the RECORD trial recently published in the European Heart Journal 
found that rosiglitazone, when used in combination therapy, doubled the risk of hospitalization 
or death from HF (OR = 2.1, 95% CI = 1.35-3.27).34 In fact, another meta-analysis of RCT data 
also revealed a doubling of the risk of death from cardiovascular disease among rosiglitazone 
users (OR = 2.37, 95% CI = 1.38-4.07).35 
 
Observational studies 
A review of observational studies also reveals the higher potential cardiovascular risks 
associated with rosiglitazone use. A retrospective cohort study of the Pharmetrics insurance 
database found a significantly higher risk for HF among diabetic patients using TZDs (OR = 
2.27, 95% CI = 1.65–3.13).36  The Institute of Clinical Evaluative Sciences in the Canadian 
Province of Ontario conducted a retrospective case-control study and identified a substantially 
higher risk of HF (RR = 1.98, 95% CI = 1.44-2.72), MI (RR = 1.76, 95% CI = 1.27-2.44), and 
death (RR = 1.47, 95% CI = 1.12-1.93) among beneficiaries aged 66 or older using rosiglitazone 
monotherapy. A statistically higher risk for HF and death was also observed among patients on 
combination therapy with rosiglitazone. 37 A retrospective cohort study in Taiwan also found a 
significant increase in risk for all cardiovascular outcomes (HR = 1.89, 95% CI = 1.57-2.28) 
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among users on rosiglitzone monotherapy as compared to metformin users.38 In fact, the risk was 
even higher for HF (HR = 2.57; 95% CI = 1.33-4.96) and MI (HR = 2.09; 95% CI = 1.36-3.24).  
 
Pioglitazone and cardiovascular risk: A comparison against rosiglitazone 
Much of the attention regarding TZD use and cardiovascular risks were initially 
attributed to Avandia® (rosiglitazone). However, since the FDA’s safety warnings in 2007 many 
studies, especially observational studies, have compared the risk of pioglitazone and 
rosiglitazone. Findings from these studies suggest that the seriousness of cardiovascular risk 
between the two TZD drugs on the market may depend upon the cardiovascular outcome. 
Retrospective cohort studies38-41 and case-control studies42,43 have found no significant 
differences in the adverse outcomes of pioglitazone versus rosiglitazone when the endpoint being 
examined is MI or death. On the contrary, other cohort studies have found that patients using 
rosiglitazone are at substantially higher risk for MI as compared to patients on pioglitazone.44,45 
For HF as the outcome of interest as much as a 12-25% lower risk has been reported with 
pioglitazone when compared to rosiglitazone.39,40,46 The Pharmetrics insurance database reveals 
that while overall TZDs significantly increase risk, pioglitazone users have about a 35% lower 
risk of HF than rosiglitazone users.36 In fact, a systematic review and meta-analysis of 16 
observational studies concluded that the odds of cardiovascular events were significantly higher 
among rosiglitazone users compared to pioglitazone users.47 Based upon a number needed to 
harm analysis, the authors reported that for every 100,000 patients who receive rosiglitazone in 
place of pioglitazone there will be 170 more MIs, 649 more HFs, and 431 excess deaths.  
Overall TZDs are shown to substantially increase the risk of cardiovascular events when 
compared to placebo or other oral hypoglycemic agents.  For example, a teleo-analysis (i.e. an 
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approach to aggregate data from different types of studies) of four observational studies and 
three randomized trials found a 55% to a 110% increase in the odds of HF among patients on 
TZDs.48 Nonetheless, the evidence does suggest that pioglitazone use is the less risky alternative. 
However, the evidence regarding pioglitazone when compared to placebo or other oral 
hypoglycemic is mixed. Some studies have not found a significant elevation in risk for negative 
cardiovascular outcomes, including HF and MI,37while other studies have found almost a 
doubling of risk.36 
 
History of cardiovascular disease, concomitant TZD use, and heart failure 
The FDA safety warnings and advisories specifically caution against the use of TZDs in 
patients with prior cardiovascular disease. 25 There is some evidence that supports these 
recommendations. A claims data study in Ontario, Canada found that prior history of 
cardiovascular disease including coronary artery disease, ischemic heart disease, and arrhythmias 
were independent predictors of heart failure among TZD users.36 However, the data suggest that 
TZD users were more likely to have advanced diabetes and poorer glycemic control and that this 
may have confounded the results.49  In a consensus statement issued by the American Diabetes 
Association and American Heart Association it is suggested that edema, a proven side-effect 
associated with TZD use, may exacerbate existing cardiovascular disease among diabetics and 
cause heart failure.50 Therefore, the apparent increase in risk of heart failure among patients with 
a history of cardiovascular disease justifies the FDA advisory that cautions against the use of 
TZDs among patients with cardiovascular disease.25   
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Contraindicated utilization of TZD in heart failure patients 
 Despite the evidence suggesting that TZD utilization is likely to exacerbate 
cardiovascular events among patients with existing heart disease, studies indicate that 
contraindicated utilization continues to remain high. An analysis of Medicare beneficiaries with 
T2DM that were hospitalized for heart failure between 1998 and 2001 revealed that 
contraindicated TZD use increased from 7.2% to 16.1%.51 However, more recently, an 
examination of the IMS National Disease Therapeutic Index (NDTI) data from 2003-2009 found 
that about a third of physicians prescribed TZDs to patients with heart disease.20 Similarly, high 
rates of inappropriate TZD use were found among commercial health plan beneficiaries. Starner 
et al. 18 examined pharmacy claims data and found that, prior to the FDA advisory in May 2007, 
25.3% of beneficiaries with rosiglitazone had higher CV risk. However, within a year following 
the FDA advisory contraindicated drug utilization declined to 21.8%. Another study among 
nationally insured patients between 65 and 69 years, in South Korea, found that TZD was used 
among 10.4% of all T2DM patients with heart failure as monotherapy and 17.9% of T2DM 
patients as combination therapy.52 Interestingly, significantly fewer patients without existing 
heart failure received TZDs.  
Given this evidence approaches to manage contraindicated TZD use is prudent. Not 
surprisingly, the FDA has attempted to control and regulate contraindicated utilization of drugs 
through a variety of public health initiatives targeted toward disseminating safety information. 
Several studies have attempted to evaluate the impact of FDA safety warnings, especially with 
regards to TZD use. 
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Safety warnings and trends in TZD utilization 
 In response to the increasing evidence of cardiovascular risk among patients taking TZDs 
the FDA issued several safety warnings and advisories prior to the implementation of REMS. 
Many of these studies implemented a time-series analytic approach to model changes in drug 
utilization. Data sources that have been evaluated include pharmacy claims data,18,19,53 
prescription audits,54 and physician surveys among T2DM patients.20 Each of these studies used 
a different approach for measuring TZD utilization. For example, the utilization measures 
selected include: the number of users with TZD, average TZD claims per day per million 
beneficiaries,18 number of prescriptions filled,19,20 number of treatment visits,54 as well as the 
percent of TZD users switching or discontinuation the drug.53 The results of these studies reveal 
that rosiglitazone use declined following the FDA warnings in May 2007.18-20,54 On the contrary, 
pioglitazone use appeared to increase and eventually stabilize.18-20,54  Overall, combined TZD 
utilization declined following the safety warnings before stabilizing.20 It has also been noted that 
utilization of other anti-diabetic drugs were not affected.19  
 
Prescriptions filled 
Stewart et al. examined temporal trends in TZD use among diabetic patients enrolled in 
TRICARE, the U.S. military health insurance program.19 Estimating a segmented regression 
model the study found a significant change in the slope and level of rosiglitazone prescriptions 
filled per month for the period following the FDA warnings in 2007.  The number of 
prescriptions filled declined by a total of 6,971 within a year after the warnings. However, 
pioglitazone fills increased by 1,507 over the same period.  
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Claims per day per million beneficiaries 
Similar changes in temporal trends of TZD use were also found in a time-series 
evaluation of pharmacy claims data from commercial plans.18 This study found that rosigltazone 
use declined in the year of the warnings by about 58%. This represented a change from a peak 
average of 99 claims per day per million members in February 2007 to an average of 41 claims 
per day per million members in December 2007. As may have been expected, rosiglitazone 
utilization declined each month following the safety warnings as compared to the stable 
utilization patterns observed prior to the warnings. A 49% and 70% decline in the daily average 
of rosiglitazone claims was observed at seven months and one year following the warnings, 
respectively. As opposed to rosiglitazone utilization patterns, the average number of daily 
pioglitazone claims remained stable in the months following the warning.   
 
Retail TZD prescriptions and TZD physician-office treatment visits 
Trend analysis of IMS’ National Prescription Audit (NPA) data revealed that 
rosiglitazone use declined by 80% in the two year period following the FDA warnings in May 
2007.54 An analysis of the IMS NDTI (nationally representative survey of physician’s office 
visits) database revealed that there was a 60% annual decline in patients treated with 
rosiglitazone from February 2007 to May 2008.20 A smaller 9% annual reduction was found for 
pioglitazone use. The aggregate use of combined TZDs had declined by 29%, annually. These 
changes were in stark contrast to the 32% and 14% annual growth in physician-office visits for 
rosiglitazone and pioglitazone, respectively, in the period preceding the FDA advisories. The 
decline in rosiglitazone use was found to stabilize about a year following the warnings. At this 
point, rosiglitazone accounted for only about 23% of total TZD use. 
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Switching and discontinuation of TZD therapy 
In a retrospective cohort of the MarketScan claims database, the safety warning for 
rosiglitazone in 2007 was found to significantly alter treatment patterns after six months.53 Over 
50% of rosiglitazone users discontinued use of the drug and about 23% of these users switched to 
pioglitazone. Fewer pioglitazone users (21.4%) had discontinued therapy. As a matter of 
concern, many of the patients that discontinued therapy did not begin treatment with another 
drug. Other cohort studies found similar results with 45% to 62% of rosiglitazone users 
discontinuing therapy within six months of the safety warning. 56,55 It appears that the small 
change in pioglitazone utilization is attributable to rosiglitazone users switching to 
pioglitazone.53  
Given the evidence, it is clear that safety warnings, advisories, and boxed warnings for 
rosiglitazone have resulted in a significant and stable decline in utilization. The safety warnings, 
in fact, benefited an uptake in pioglitazone use. However, a better measure of the effectiveness of 
safety warnings than overall TZD utilization would be a demonstrable effect on curbing TZD use 
among contraindicated diabetic patients 
 
Safety warnings and trends in contraindicated TZD utilization 
Research studies suggest that effect of safety warnings for TZD on mitigating 
contraindicated TZD use among patients with a history of cardiovascular disease appear to be 
mixed.18,20 Cohen et al. found that contraindicated prescribing of TZDs to patients with 
cardiovascular disease amounted to about a third of all TZD use.20 In fact, the proportion of 
contraindicated TZD use remained stable from 2003 to 2009, suggesting that the safety warnings 
might have only resulted in a decline of total TZD use. In comparison, Starner et al. 18 found that 
about 25% of TZD users in their study had cardiovascular risk factors prior to the safety 
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warnings being issued. However, contraindicated use declined to 22.5% six months after the 
warnings. Among the contraindicated risk factors, the utilization of rosiglitazone among patients 
with heart failure was found to decline from 2.8% to 2.0% a year following the safety warnings. 
These finding reveal that inefficiencies exist in the effect of safety warnings on utilization. This 
is because safety warnings appear to have a greater effect in reducing the utilization of TZD in 
patients who may benefit from the drug. 
 
Figure III: Graphical Representation of REMS Effectiveness on Appropriate Utilization 
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FDA safety warnings for other drugs 
 The effect of safety warnings on drug utilization have also been examined for 
troglitazone used in the treatment of type 2 diabetes (increases risk of liver disease),57 cisapride 
that is used in the treatment of heartburn (increases risk of cardiac arrhythmias),57,58 
antidepressants (increases risk of suicidal thoughts among children),59-61 and atypical 
antipsychotics among patients with dementia (increases risk of cerebrovascular disorders and 
death).62,63   
 Troglitazone was the first TZD approved in the U.S. and was withdrawn because it was 
found to result in excessive cases of liver disease. A study among Idaho Mediaid patients found 
that FDA warnings regarding the risk of liver disease associated with troglitazone use resulted in 
a slow, but steady, change in drug utilization.57 There was an initial decline in new prescriptions 
dispensed. However, as evidence of troglitazone adverse effects accumulated and additional 
advisories were issued a significant decline in total and new prescription volume was observed. 
Similar patterns of use were found following labeling changes and the issuance of FDA 
advisories that cautioned against the contraindicated use of cisapride for the treatment of 
heartburn.57 One study found that “Dear Health Professional” letters that were mailed out to 
inform physicians about cisapride resulted in only a negligible decline in the proportion of 
contraindicated cisapride users.58 However, overall contraindicated use of cisapride among 
Medicaid beneficiaries was high at about 60% of total use. As compared to managed care 
beneficiaries, contraindicated use among Medicaid beneficiaries was almost double. 
 In the year 2003, a public health advisory regarding the risk of suicide among children 
using paroxetine was issued. Pamer et al.59 examined paroxetine utilization trends and found that 
the drug’s use among children declined in the period following the advisory. Similar results were 
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also found in an evaluation of Medco’s prescription database, wherein a 36% annual increase in 
antidepressant use was recorded before the safety warnings, while a 10% decline in annual use 
following the boxed warnings.64 A 54% decline in the use of SSRIs was reported following 
suicide risk advisories among Canadian patients younger than 20 years.61 However, no decline 
was found among adults.  
Time series analysis of atypical antipsychotic use among patients with dementia indicated 
that FDA warnings had the intended effect on utilization patterns. A significant decline was 
observed from 12 to 24 months following FDA safety and black box warnings as compared to 
the period before the warnings. These findings were observed in the U.S. Veterans Affairs 
prescription claims database63 and in Ontario, Canada.62  
 
Hypothesis 
In summary, there is ample evidence that safety warnings can be an effective tool to 
decrease drug utilization. However, the effect of such warnings, including boxed warnings, 
“Dear Health Professional” letters, and FDA advisories on contraindicated drug utilization has 
not been consistently demonstrated. Nonetheless the expectation is that REMS will have a 
significant impact on fulfilling its objectives, i.e. preventing contraindicated drug utilization. 
This study therefore hypothesizes the following: 
 
Hypothesis 1: Medication guides as REMS will result in a significant decline in (a) total 
contraindicated TZD utilization, and (b) new contraindicated TZD utilization. 
 
Hypothesis 2: Medication guides as REMS will not result in a significant decline in (a) total 
non-contraindicated TZD utilization, and (b) new non-contraindicated TZD utilization. 
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III. METHODOLOGY 
 
Data source 
Mississippi Medicaid data from 2008 to 2012 was used to assess the effect of REMS on 
contraindicated drug utilization patterns. The timeframe proposed at the time of writing this 
proposal was 2008-2010 but was extended to be more inclusive and to account for new events 
occurring in 2011 and 2012. Mississippi Medicaid is a healthcare program that is operated by the 
state and funded by both the state and federal governments. It provides medical coverage for 
qualifying low income individuals and families. Mississippi Division of Medicaid, similarly to 
other state Medicaid programs, establishes the eligibility criteria, covered services, and payment 
rates under federal guidelines.71 
De-identified data for all Medicaid beneficiaries from the year 2008 to 2012 was acquired 
from the Mississippi Division of Medicaid under a Data User Agreement (DUA) through the 
Evidence-Based DUR Initiative- MS-DUR. Available data files include the beneficiary 
characteristic file, provider description file, medical claims file, and prescription claims file. The 
beneficiary characteristic file is a person level file that contains demographic and eligibility data 
of the Medicaid recipient. The provider description file is a person level file that contains 
demographic data regarding the providers practice, including specialty type. The medical claims 
file contains event level data regarding diagnoses, procedures, and charges associated with the 
healthcare service provided. The pharmacy file contains event level prescription information 
including prescription identification, drug codes and days of supply, and drug charges.
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Drug selection 
Contraindicated drug utilization for the thiazolidenedione (TZD) drug class, comprising 
of rosiglitazone and pioglitazone, were selected to evaluate the effect of medication guide 
REMS. TZDs were chosen following an elaborate and practical evaluation of all REMS 
programs approved by the FDA. A list of FDA approved REMS from the FDA’s website72 was 
aggregated and reviewed based on the following guidelines: (1) The date of REMS approval for 
the drug must present a 12 month follow-up period to evaluate changes in contraindicated drug 
utilization trends; (2) The objective of REMS for the drug must be to mitigate the risk of 
contraindicated drug utilization; (3) The identification of patients with contraindicated drug use 
must be possible though medical or pharmacy claims data; (4) The adverse outcomes that the 
approved REMS is expected to mitigate must be associated with its contraindicated use; (5) 
Sufficient cases of contraindicated drug use must exist to permit statistical evaluations of REMS 
effectiveness.   
Two pharmacists affiliated with the School of Pharmacy at the University of Mississippi 
and with over 5 years of clinical practice experience were recruited to independently evaluate the 
REMS list based on these guidelines. Both pharmacists possess a Doctor of Pharmacy degree. 
Pharmacist 1 was the Clinical Director of the MS-DUR and a Research Assistant Professor in 
the Center for Pharmaceutical Marketing and Management. Pharmacist 2 is a Certified Diabetes 
Educator and an Assistant Professor of Pharmacy Practice. Based on the stated criteria both 
pharmacists judged TZDs to be the most appropriate drug class for analysis.   
Based on the selection guidelines TZDs were selected as the target drug category for 
analysis since they permitted a 12 month pre-REMS and post-REMS evaluation period because 
REMS for rosiglitazone were approved on December 28, 2008 and REMS for pioglitazone were 
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approved in September, 2009;  T2DM patients with a history of cardiovascular disease and 
concurrent TZD use can be identified in the Medicaid claims data; and  a preliminary analysis of 
the Mississippi Medicaid data revealed that there are adequate cases in the Medicaid data to 
permit an evaluation of the research objectives.  
Multaq®, for the treatment of atrial flutter, and Effient®, for the treatment of acute 
coronary syndrome, were also recommended by the pharmacist panel as possible target drug 
classes for the analysis. However, insufficient data was available to permit an evaluation of the 
effect of REMS associated with contraindicated utilization of these drugs. 
 
Study Design 
 This study implemented a retrospective quasi-experimental interrupted time-series design 
using Mississippi Medicaid data from 2008 to 2012. TZD utilization trends among T2DM 
patients with prior heart failure (i.e. contraindicated TZD use) before and after the approval of 
REMS is the outcome of interest. The date of REMS approval for each TZD is the intervention 
of interest and marks the end of the pre-REMS segment (or pre-intervention period) and the start 
of the post-REMS segment (or post-intervention period).  
Medication guides for rosiglitazone products were approved in 2008 (Table I). 
Specifically, medication guides for Avandaryl® and Avandamet® were approved in December 
2008. A medication guide for Avandia® was approved under the FDA’s RiskMAP program in 
February 2008. Under FDA guidelines the RiskMAP medication guide was considered to be a 
REMS medication guide as of December 2008.  Medication guides for pioglitazone products 
(Actos®, Actoplus Met®, and Duetact®) were approved in September 2009. T2DM patients will 
be tracked for TZD utilization every month during the pre-intervention period and during the 
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post-intervention period. Monthly TZD utilization will be assessed among contraindicated and 
non-contraindicated patients using medical and pharmacy claims. Specifically, the measures to 
be assessed are the number of new and total patients with a contraindicated TZD claim and the 
new and total number of patients with a non-contraindicated TZD claim before and after REMS 
implementation. 
In addition, as the time frame of the data analysis was extended through December 2012, 
the impact of multiple additional events that occurred following the introduction of the MG 
REMS for rosiglitazone and pioglitazone were also evaluated. These include: 
May 2010 – An updated meta-analysis study that was accepted for publication in the 
medical journal, JAMA, in May 2010 and published in June 2010.26 This also coincided with 
media reports that GSK had begun to settle lawsuits related to the use of Avandia.73 
September 2010 – The FDA severely restricts use of rosiglitazone only to patients who 
are uncontrolled on other diabetes medications. The European Medicines Agency (EMA) 
recommends the suspension of rosiglitazone use in member nations. 74,75 
November 2010 – MS Medicaid’s Drug Utilization review board decided to remove 
rosiglitazone from its preferred drug list thus limiting access to the product.76 
February 2011 – FDA issues notifications to physicians enforcing its recommendation to 
limit rosiglitazone use in uncontrolled patients, with updated label warnings.77 
May 2011 – FDA updates the REMS for rosiglitazone to include the most restrictive 
ETASU strategy which restricted access and distribution of rosiglitazone.78 
July 2012 – GSK pleads guilty for failing to report safety concerns with Avandia and 
agrees to the largest health care fraud settlement, $3 billion, at the time in the US.79 
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Table I: Dates of Events 
Time Event 
December 2008 MG REMS introduced for rosiglitazone 
September 2009 MG REMS introduced for pioglitazone 
May 2010 Widely publicized JAMA study demonstrating risk of TZDs26 
September 2010 FDA restricts use of rosiglitazone to uncontrolled patients (also EU) 
November 2010 MS Medicaid takes rosiglitazone off its preferred product list 
February 2011 FDA notifies physicians about updated label warnings for TZDs 
May 2011 REMS for rosiglitazone extended to include ETASU 
July 2012 GSK settles a $3 billion lawsuit for Avandia 
 
Data is unavailable to track and model the effect of safety warnings and advisories that 
were issued prior to 2008. The lack of available data prior to 2008 limits the ability of this study 
to examine trends in utilization to segment and control for the introduction of Avandia’s 
medication guide RiskMAP introduction in February 2008 and more importantly the safety 
warnings issued in May 2007. 
 
Patient selection 
 T2DM patients utilizing TZDs with or without pre-existing diagnosis for heart failure 
will be identified by matching International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes with inpatient and medical claims and National Drug 
Codes (NDCs) with pharmacy claims. The following approach will be followed: 
1. Select beneficiaries with T2DM  
2. Identify TZD users and days with TZD supply following date of T2DM diagnosis 
3.  Identify beneficiaries with pre-existing heart failure  
4. Identify beneficiaries with contraindicated TZD claims (TZD use following heart failure 
diagnosis) 
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Figure IV: Illustration of Patient Selection and Measures 
 
 
Select beneficiaries with Type 2 Diabetes Mellitus 
 Medicaid beneficiaries with a diagnosis of T2DM were eligible for inclusion in the study. 
Dual eligible beneficiaries were excluded. Beneficiaries were identified to be suffering from 
T2DM if they met any one of the following criteria: (1) at least one International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for diabetes (250.x0 or 
250.x2) in the Medicaid medical claims file; (2) at least two claims for any oral hypoglycemic 
agent (biguanides, sulfonylureas, thiazolidinediones, α-glucosidase inhibitors, and non-insulin 
secretagogues); or (3) at least one claim for more than a 30 days’ supply of any oral 
hypoglycemic agent (OHG) over a 6 month period.36 Beneficiaries identified using the OHG 
criteria will be excluded if they have a diagnosis for polycystic ovary syndrome (ICD-9-CM 
256.4) and no ICD-9-CM for T2DM. OHG’s are indicated for the management of polycystic 
ovary syndrome and may therefore not confirm a T2DM diagnosis. NDC codes for OHG agents 
will be compiled using the Multum drug database and matched with the pharmacy claims file. 
The dates associated with each of these criteria were flagged and the index date for a T2DM 
diagnosis was considered to be the earliest date of a confirmed diagnoses. The beneficiary was 
entered into the study at their T2DM index date. 
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 A cohort of T2DM patients identified using only the second and third criterion as 
specified above was also created. This cohort was created to define a constant denominator to 
track the change in prescribing trends of TZD among treated T2DM beneficiaries. These patients 
were selected if the first day of OHG possession was identified to be in the first four months of 
2008 as the timeline would permit the identification of beneficiaries receiving an OHG 
prescription with 90 days’ supply. 
 
Identify TZD users  
TZD use for each beneficiary with a T2DM diagnosis on or after the date of diagnosis 
was identified using NDC codes. NDC codes for each TZD were compiled using the Multum 
drug database and matched with the pharmacy claims file to flag TZD utilization. This file is the 
denominator file for the study as it includes T2DM patients utilizing TZDs. Each TZD was also 
re-coded at the generic drug level to identify rosiglitazone and pioglitazone users. Possession of 
TZD was tracked for each day over the analysis period using the days supply field to identify 
days with contraindicated TZD utilization. Benefit design constraints to TZD use were not 
present in Mississippi Medicaid as all TZDs were listed in on the preferred drugs list (PDL) 
during the analysis period.  
 
Identify beneficiaries with pre-existing heart failure 
Beneficiaries with pre-existing heart failure were identified using ICD-9-CM codes that 
have been developed by the Chronic Condition Data Warehouse (CCDW) to define chronic 
conditions including heart failure (Table II).80 This definition for heart failure has been found to 
accurately identify patients with heart failure in administrative claims data. Birman-Deych et al. 
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recorded a sensitivity = 0.76, specificity = 0.97, positive predictive value = 0.97, and negative 
predictive value = 0.74 in hospital claims for Medicare beneficiaries when the diagnosis is 
recorded in any position.81 Therefore, patients with at least one medical claim with a primary or 
secondary diagnosis for heart failure were identified.80 The date of diagnosis was flagged as the 
index date for the heart failure diagnosis. Beneficiaries were then tracked for concurrent use of 
TZDs each month of the study period.  
Additionally, given the extensive evidence regarding other cardiovascular risk factors, 
including myocardial infarction (MI) and ischemic heart disease (IHD), concurrent utilization of 
TZDs among beneficiaries with these risk factors were also assessed. Beneficiaries with IHD 
were also identified using diagnosis codes and medical procedure codes as developed by CMS 
(for CCDW) to define chronic conditions.80 CCDW’s definition for IHD includes MI. Utilization 
of TZDs following an IHD diagnosis date was also considered to be contraindicated use. 
Birman-Deych et al. found a high predictive accuracy for the diagnosis codes that will be utilized 
to identify IHD. However, the CCDW definition for IHD also includes procedure codes and 
HCPCS payment codes in addition to ICD-9-CM diagnosis codes. 
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Table II: Diagnosis Codes Used for Patient Selection 
 
HEART FAILURE 
 
398.91    RHEUMATIC HEART FAILURE 428.21    AC SYSTOLIC HRT FAILURE  
402.01    MAL HYPERT HRT DIS W CHF 428.22    CHR SYSTOLIC HRT FAILURE  
402.11    BENIGN HYP HRT DIS W CHF 428.23    AC ON CHR SYST HRT FAIL  
402.91    HYPERTEN HEART DIS W CHF 428.9      HEART FAILURE NOS 
404.01    MAL HYPER HRT/REN W CHF 428.30    DIASTOLIC HRT FAILURE NOS  
404.03    MAL HYP HRT/REN W CHF&RF 428.31    AC DIASTOLIC HRT FAILURE  
404.11    BEN HYPER HRT/REN W CHF 428.32    CHR DIASTOLIC HRT FAIL  
404.13    BEN HYP HRT/REN W CHF&RF 428.33    AC ON CHR DIAST HRT FAIL  
404.91    HYPER HRT/REN NOS W CHF 428.40    SYST/DIAST HRT FAIL NOS  
404.93    HYP HT/REN NOS W CHF&RF 428.41    AC SYST/DIASTOL HRT FAIL  
428.0      CONGESTIVE HEART FAILURE 428.42    CHR SYST/DIASTL HRT FAIL  
428.1      LEFT HEART FAILURE 428.43    AC/CHR SYST/DIA HRT FAIL  
428.20    SYSTOLIC HEART FAILURE NOS  
 
ISCHEMIC HEART DISEASE 
DIAGNOSIS CODES 
410.00, 410.01, 410.02, 410.10, 410.11, 410.12, 410.20, 410.21, 410.22, 410.30, 410.31, 410.32, 
410.40, 410.41, 410.42, 410.50, 410.51, 410.52, 410.60, 410.61, 410.62, 410.70, 410.71, 410.72,  
410.80, 410.81, 410.82, 410.90, 410.91, 410.92, 411.0, 411.1, 411.81, 411.89, 412, 413.0, 413.1, 
413.9, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06, 414.07, 414.10, 414.11, 414.12,  
414.19, 414.2, 414.3, 414.8, 414.9 
 
PROCEDURE CODES 
 00.66, 36.01, 36.02, 36.03, 36.04, 36.05, 36.06, 36.07, 36.09, 36.10, 36.11, 36.12, 36.13, 36.14, 
36.15, 36.16, 36.17, 36.19, 36.2, 36.31, 36.32 
 
HCPCS CODES 
33510, 33511, 33512, 33513, 33514, 33515, 33516, 33517, 33518, 33519, 33521, 33522, 33523, 
33533, 33534, 33535, 33536, 33542, 33545, 33548, 92975, 92977, 92980, 92982, 92995, 33140, 
33141 
 
 
Identify beneficiaries with contraindicated TZD claims 
Contraindicated use of TZDs is defined as the initiation of TZDs among diagnosed heart 
failure patients or the continued use of TZDs following a heart failure diagnosis. Therefore, the 
contraindicated users of TZDs will include those beneficiaries with days of supply for a TZD 
that overlaps or follows the index date of heart failure diagnosis. The earliest date of overlapping 
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use is the index date of contraindicated TZD use. The non-contraindicated patient group includes 
those T2DM beneficiaries taking TZDs but do not have cardiac disease. Utilization of TZDs 
among patients with IHD was also independently assessed. 
 
Measures for TZD utilization 
 To examine the change in utilization of TZDs following the approval of medication guide 
as REMS this study assessed several measures of contraindicated and non-contraindicated TZD 
utilization. These measures include monthly estimates of new and total contraindicated TZD 
utilization. These measures were computed for patients with contraindicated utilization of TZD 
and compared with patients with non-contraindicated utilization of TZDs, separately for 
rosiglitazone and pioglitazone. This analysis was conducted by tracking all eligible T2DM 
patients each month and by tracking a fixed cohort of eligible patients identified in the first four 
months of the analysis period. 
 
Total contraindicated TZD utilization: Total TZD utilization is defined as the proportion of 
beneficiaries with an active supply for a contraindicated TZD. For this measure, beneficiaries 
will be recorded as using a TZD for the days of TZD supply + 1, from the index date of the 
prescription claim. If a beneficiary has at least 7 days of supply (ds) each month they will be 
considered to have an active prescription that month. This enables the assessment of 
contraindicated utilization among beneficiaries receiving greater than a 30 day supply of a TZD, 
especially if started mid-month, and ensures that TZD possession is not underestimated. This 
measure will be assessed (1) among all eligible patients each month, and (2) among a fixed 
cohort of patients identified with T2DM in the first four months of 2008. The objective of this 
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measure is to examine changes in the pattern of contraindicated TZD use before and after REMS. 
This measure will also be expressed by tracking the proportion of contraindicated TZD use 
among all eligible T2DM patients each month. The purpose of tracking the proportion of 
contraindicated T2DM use is to examine the change in total contraindicated TZD use relative to 
all eligible T2DM patients each month. 
 
New contraindicated TZD utilization: New TZD utilization was defined as the proportion of 
beneficiaries with a new or reauthorized contraindicated TZD prescription claim. Therefore, the 
prescription claim was either the first TZD claim following a T2DM diagnosis or one with a 
different prescription number from the previous TZD claim. The change in prescription number 
for a TZD is expected to capture beneficiaries that are receiving a new prescription authorization 
from their physician and not a refill. Utilization was tracked each month pre and post REMS 
approval. This measure will be assessed (1) among all eligible patients each month, and (2) 
among a fixed cohort of patients identified with T2DM in the first four months of 2008. The 
objective of this measure is to examine changes in the pattern of new contraindicated TZD 
claims before and after REMS i.e., are there new starts for TZDs following the events. This 
measure will also be expressed by tracking the proportion of contraindicated TZD use among 
new eligible T2DM patients each month. The purpose of tracking the proportion of 
contraindicated T2DM use is to examine the change in contraindicated TZD use relative new 
T2DM patients each month.  
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Statistical Analysis 
Descriptive statistics (means and frequencies) of patient demographic and clinical 
characteristics (other OHG therapy and comorbidity score) will be computed.  
 Segmented regression analysis was used to assess the effectiveness of REMS on TZD 
utilization. This time-series approach was judged to be appropriate to test the hypothesis that 
REMS approval results in a decline in new contraindicated TZD utilization and total 
contraindicated TZD utilization. Segmented regression is a strong quasi-experimental technique 
that permits the testing of the effect of a policy or intervention i.e. REMS.63,82,83 It is argued that 
this technique provides more valid evidence of the effectiveness of interventions than a pre/post 
design as it controls for pre-intervention trends.63,84 For this analysis, monthly data was modeled 
for the pre-REMS and the post-REMS periods. Months were coded in relative terms to allow an 
easier interpretation of utilization. A segmented regression model was then specified to include 
an intercept (to test the immediate effect on utilization at REMS approval) and a slope (change in 
use at specific time compared to before REMS).85 It is suggested that there be at least 12 time 
points before and after the intervention for appropriate trend analysis and this study allows that.  
 
Rx = intercept + (p,d,q) + B0 + B1*montht + B2*Eventt + B3*EventMontht + … + et 
 
 Rx is the outcome variable and represents the utilization rate of TZDs drugs in month t 
 Intercept is the monthly utilization rate before the intervention 
 Montht is the time in months over the entire observation period 
 Eventt is an indicator for time t before and after the REMS intervention 
 EventMontht is the number of months after the REMS intervention at time t  
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 B0 estimates the utilization rate at time zero 
 B1 estimates the change in utilization rate each month before the REMS intervention 
 B2 estimates the change in the utilization rate immediately after the REMS intervention 
(repeated for each intervention) 
 B3 estimates the change in monthly utilization rates each month after the REMS 
intervention (repeated for each intervention) 
The Autoregressive Moving Averages (ARIMA) technique (Proc ARIMA, SAS 9.2, Cary 
NC) was used to model any stationarity and correct for possible autocorrelations between the 
residuals for each time period. For this, inverse and partial autocorrelation functions of the 
residuals were assessed using the Ljung-Box and Box-Pierce statistics. The identified model is 
then to graph the observed values. In the equation specified above, (p,d,q) describe the following 
elements that are identified in fitting the ARIMA model. 
 Auto-regressive element (p) – Lingering effects of preceding scores (Specifies the 
dependencies among observations) 
 Integrated elements (d) –Trends in the data (Converts non-stationary data to stationary 
data) 
 Moving averages (q) – Lingering effects of random shocks 
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IV. RESULTS 
 
Description of Sample 
57,114 eligible T2DM patients, 1,411 rosiglitazone users, 3,188 pioglitazone users, and 
13,987 patients with HF or IHD were identified in the MS Medicaid sample over the analysis 
period (Table III). The greatest proportion of contraindicated rosiglitazone and pioglitazone use 
at any point in the analysis was 17.8% (280/1,573) and 21.4% (770/3,588) respectively.  
The incidence of T2DM, consequent TZD use and HF/IHD within the MS Medicaid 
population was found to be greater in females than males. This pattern was consistent among 
contraindicated and non-contraindicated TZD users, even though a relatively smaller proportion 
of females are diagnosed with HF or IHD. The incidence of T2DM, consequent TZD use and 
HF/IHD within the MS Medicaid population was found to be greater among blacks than whites. 
Similar to gender, this pattern was consistent among contraindicated and non-contraindicated 
TZD users, even though a relatively smaller proportion of blacks are diagnosed with HF or IHD. 
The average age of T2DM patient and non-contraindicated TZD users within the MS Medicaid 
population was found to be about 49 years old. However, the average age of patients with a HF 
or IHD diagnosis and contraindicated TZD use was found to be incrementally higher at 55 and 
53 years of age respectively.  
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Table III: Description of Total Eligible Sample 
  
T2DM 
Patients 
Rosiglit-
azone 
Pioglit-
azone 
HF/IHD 
Contra-
indicated 
ROS 
Contra-
indicated 
PIO 
Non-
contra-
indicated 
ROS 
Non-
contra-
indicated 
PIO 
N 57,114 1,573 3,588 13,987 280 770 1,293 2,818 
Gender 
Male 28.9% 24.9% 24.6% 33.5% 28.9% 31.0% 24.2% 23.7% 
Female 71.1% 75.1% 75.4% 66.5% 71.1% 69.0% 75.8% 76.3% 
 Race 
White 33.0% 27.4% 26.8% 35.6% 28.6% 28.3% 26.8% 26.4% 
Black 58.9% 62.3% 64.0% 56.3% 61.4% 63.6% 62.7% 64.3% 
Hispanic 0.6% 0.4% 0.4% 0.3% 0.0% 0.3% 0.4% 0.5% 
Other 7.4% 10.0% 8.8% 7.9% 10.0% 7.8% 10.1% 8.8% 
Age 
Mean 48.6 49.5 49.6 54.7 53.0 52.9 49.2 49.3 
SD 18.9 11.7 11.2 12.7 8.3 8.1 11.9 11.5 
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Figure V: Description of Patient Cohort – Total Patients 
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For the fixed cohort of eligible T2DM patients (defined as patients with a TZD claim 
identified in the first 4 months of the analysis period), 1,411 rosiglitazone and 3,195 pioglitazone 
users were identified. Among these patients, 7.9% were identified as contraindicated 
rosiglitazone and 10.9% as contraindicated pioglitazone patients at any point in the analysis 
period (Table IV). Similar demographic patterns were observed with the restricted sample as 
were observed with the full sample. 
 
Table IV: Description of Fixed Sample (Identified in First 4 Months of Analysis Period) 
  Contraindicated ROS Contraindicated PIO 
Non-contraindicated 
ROS 
Non-contraindicated 
PIO 
N 112 348 1,299 2,847 
Gender 
Male 32.1% 31.3% 24.3% 23.8% 
Female 67.9% 68.7% 75.8% 76.2% 
Race 
White 34.8% 29.9% 26.7% 26.5% 
Black 56.3% 61.5% 62.8% 64.2% 
Hispanic 0.0% 0.0% 0.4% 0.5% 
Other 8.9% 8.6% 10.1% 8.9% 
Age 
Mean 53.0 52.0 49.2 49.3 
SD 7.6 8.4 11.9 11.5 
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Figure VI: Description of Patient Cohort –Fixed Cohort Identified in First 4 Months of Analysis Period 
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Statistical Diagnosis of ARIMA Models 
PROC ARIMA was used to control for autocorrelation and to assess stationarity of the 
data prior to modeling the results. Modeling the data using PROC ARIMA helps control for 
inherent patterns in the data that may dampen the testing of an intervention and may otherwise 
increase the type 1 error rates due to autocorrelations. The following steps were followed in 
building the model as suggested by Tabachnik and Fidell (2007).87 
 
Identification: The purpose of this step was to identify whether the data has autoregressive (p), 
integrated (d) or moving average (q) elements. In order to complete this step, the data was 
plotted to test if the trends in the data around the mean were stationary. If needed, the data was 
de-trended by differencing. Differencing is achieved by subtracting the value for each time point 
from the preceding value. Differencing of the data was considered until the data becomes 
stationary as tested by the Augmented Dickey-Fuller test. Transformation of the values was 
considered if the variances at each time point changes. All measures evaluated in the research 
required one order of differencing. Autocorrelation Functions (ACF) and Partial Autocorrelation 
Functions (PACF) were also used to help identify (1) if autoregressive and moving average 
parameters need to be included, and (2) the order of the parameters. Deviations from a zero 
autocorrelation indicate the data is not white-noise and as such has lingering effects of preceding 
scores (autoregressive parameter) or lingering effects of random shocks (moving average 
parameters). Identifying and modeling these parameters ensures white noise data is modeled. 
ESACF, SCAN and MIMIC functions in PROC ARIMA were also used to identify potential 
ARIMA candidate models as they identify all significant AR and MA model orders. Models 
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suggested by these functions were also tested to confirm the most parsimonious model choice 
that results in white-noise. 
 
Estimation: The model was then estimated by including all significant (p,d,q) parameters which 
account for any lingering patterns in the data. 
 
Diagnosis: The estimated model was checked to ensure there were no unaccounted for patterns. 
In order to test for this, each of the following were examined; (1) normality of distribution of 
residuals, (2) plots for homogeneity of variance over time, (3) independence of residuals, and (4) 
absence of outliers. Autocorrelation check for white noise was tested for non-significance. If no 
significant ACFs and PACFs exist, the model is deemed to fit well and account for all systematic 
patterns. A non-significant Box-Ljung statistic confirms the presence of white noise and was 
used as a diagnostic test. PROC AUTOREG was used as an additional approach to confirm for 
the presence of autocorrelations using the Durbin Watson statistic.  
 
Using these approaches, all models were differenced to de-trend the data prior to 
estimating the autoregressive and moving average parameters. The autocorrelation check for 
white noise was non-significant, indicating no discrepancy between the model and data. The full 
model was run with the REMS event dates and all subsequent events as interventions. The most 
parsimonious model was identified by iteratively deleting predictors with parameters having the 
largest ‘p value’ and testing to see if the parsimonious model has significantly better model fit 
than the more complex model i.e., a model with the lowest AIC & BIC but significant AR and 
MA coefficients. 
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Total Contraindicated and Non-Contraindicated Use (Total Sample) 
Contraindicated rosiglitazone use:  
The contraindicated rosiglitazone use model required one order of differencing to de-
trend the data and has a significant autoregressive parameter. The full model (Table V) has a 
significant intercept indicating there were 12 (coefficient = 12.18, p < 0.001) contraindicated 
rosiglitazone patients at the beginning of the observation period. A significant parameter 
indicates there is a month-to-month decline of 1 contraindicated rosiglitazone patient prior to the 
intervention period (coefficient = -0.87, p = 0.03). The REMS program for rosiglitazone and 
pioglitazone had no immediate or month-to-month significant impact on contraindicated 
rosiglitazone utilization. A parsimonious model (Table VI) was fitted by the step-wise removal 
of non-significant parameters to obtain a statistically better model as measured by AIC and BIC. 
This model demonstrated a similar effect with a significant intercept, month-to-month change 
prior to the intervention, and no impact on prevailing utilization following REMS for 
rosiglitazone and pioglitazone in December 2008 and September 2009, respectively. However, 
significant intervention effects were observed in May 2010 (immediate and month-to-month 
intervention effect), September 2010 (immediate and month-to-month intervention effect), 
February 2011 (month-to-month intervention effect), and May 2011 (month-to-month 
intervention effect). These latter events had no meaningful impact on the overall utilization of 
rosiglitazone which is observed to have been on a declining trend prior to the observation period 
and already very low during the observation (Figure VII). In fact, rosiglitazone use was observed 
to drop almost to 0 following removal from the MS Medicaid preferred drug list in November 
2010. 
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Non-Contraindicated rosiglitazone use:  
The non-contraindicated rosiglitazone use model required one order of differencing to de-
trend the data and achieve white-noise. No autoregressive or moving average parameters were 
needed to be modeled. The full model (Table V) had a significant intercept indicating there were 
43 (coefficient = 42.72, p = 0.01) contraindicated rosiglitazone patients at the beginning of the 
observation period. A significant month-to-month decline of 7 non-contraindicated rosiglitazone 
patients prior to the intervention period (coefficient = -6.79, p < 0.01) was also observed. The 
REMS program for rosiglitazone had a small month-to-month positive impact on rosiglitazone 
that approached significance, with non-contraindicated rosiglitazone use increasing by 6 patients 
(coefficient = 6.07, p = 0.08) each month following the intervention. REMS for pioglitazone had 
no immediate or month-to-month significant impact on non-contraindicated rosiglitazone 
utilization. A parsimonious model (Table VI) was fitted by the step-wise removal of non-
significant parameters to obtain a statistically better model as measured by AIC and BIC. This 
model demonstrated a similar effect with a significant intercept, month-to-month change prior to 
the intervention, and a now significant month-to-month increase in non-contraindicated 
rosiglitazone use following REMS for rosiglitazone in December 2008. REMS for pioglitazone 
has no significant impact. In addition, a significant change in use was observed in November 
2010 (month-to-month intervention effect), February 2011 (month-to-month intervention effect), 
and May 2011 (month-to-month intervention effect). However, these events had no meaningful 
impact on the overall non-contraindicated utilization of rosiglitazone which is observed to have 
been on a declining trend prior to the observation period and already very low (approach 0) 
during the observation (Figure VII).  
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Contraindicated pioglitazone use:  
The contraindicated pioglitazone use model required one order of differencing to de-trend 
the data and achieve white-noise. No autoregressive or moving average parameters needed to be 
modeled. The full model (Table V) has a significant intercept indicating there were 29 
(coefficient = 29.01, p < 0.01) contraindicated pioglitazone patients at the beginning of the 
observation period. The parameter for the month-to-month change prior to the intervention 
period approached statistical significance suggesting a decline of 3 contraindicated pioglitazone 
patients each month prior to the intervention (coefficient = -2.68, p = 0.05). The REMS program 
for rosiglitazone and pioglitazone had no immediate or month-to-month significant impact on 
pioglitazone utilization. A parsimonious model (Table VI) was fitted by the step-wise removal of 
non-significant parameters to obtain a statistically better model as measured by AIC and BIC. 
This model demonstrated a similar effect with a significant intercept, a now significant month-to-
month change prior to the intervention, and no impact on existing trends following REMS for 
rosiglitazone and pioglitazone in December 2008 and September 2009 respectively. In addition, 
significant interventions were observed in May 2010 (month-to-month intervention effect), 
November 2010 (month-to-month intervention effect), February 2011 (month-to-month 
intervention effect), and May 2011 (month-to-month intervention effect). These latter events had 
a small temporary effect on the overall contraindicated utilization of pioglitazone (Figure VII). In 
fact, contraindicated pioglitazone use also dropped along with rosiglitazone to less than 0.5% of 
all T2DM patients following the loss of the latter’s preferred status in November 2010 (Figure 
VIII) 
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Non-Contraindicated pioglitazone use:  
The non-contraindicated pioglitazone use model required one order of differencing to de-
trend the data and achieve white-noise. No autoregressive or moving average parameters to 
account for random shocks needed to be modeled. The full model (Table V) has a significant 
intercept indicating there were 74 (coefficient = 74.37, p = 0.01) non-contraindicated 
pioglitazone patients at the beginning of the observation period. The parameter for the month-to-
month change prior to the intervention period was significant suggesting a decline of 11 non-
contraindicated pioglitazone patients each month prior to the intervention (coefficient = -10.7, p 
= 0.01). The REMS program for rosiglitazone had a small month-to-month positive impact on 
non-contraindicated pioglitazone that approached significance, with non-contraindicated 
pioglitazone use increasing by 11 patients (coefficient = 11.2, p = 0.08) each month following 
the intervention. REMS for pioglitazone had no immediate or month-to-month significant impact 
on non-contraindicated pioglitazone utilization. A parsimonious model (Table VI) was fitted by 
the step-wise removal of non-significant parameters to obtain a statistically better model as 
measured by AIC and BIC. A significant intercept, month-to-month change prior to the 
intervention, and a month-to-month increase in non-contraindicated pioglitazone use (now 
statistically significant) was observed following REMS for rosiglitazone. In addition, a 
significant month-to-month decrease in non-contraindicated pioglitazone use was observed in 
November 2010 (immediate and month-to-month intervention effect) following the loss of 
rosiglitazone preferred status in MS Medicaid (drop from 3% to less than 1%, Figure VIII). The 
February 2011 (month-to-month intervention effect), and May 2011 (month-to-month 
intervention effect) interventions were also significant but not meaningful in its impact on non-
contraindicated pioglitazone use (Figure VII).  
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Table V: Total Contraindicated and Non-Contraindicated TZD Use (Full Model) 
Total Model 
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
  Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept 12.18 <0.01 29.01 <0.01 42.72 0.01 74.37 0.01 
AR1,1 -0.46 <0.01            
Month -0.87 0.03 -2.68 0.05 -6.79 <0.01 -10.70 0.01 
Event_Dec08 -0.83 0.81 10.51 0.37 24.31 0.21 30.31 0.39 
Event_Dec08_M 0.65 0.26 1.58 0.46 6.07 0.08 11.20 0.08 
Event_Sep09 2.95 0.42 6.49 0.61 17.87 0.38 1.23 0.97 
Event_Sep09_M -0.90 0.20 -0.63 0.81 -2.65 0.52 -0.26 0.97 
Event_May10 -11.94 0.04 -11.62 0.51 -12.27 0.67 -21.63 0.68 
Event_May10_M 5.71 <0.01 11.36 0.06 9.93 0.31 8.12 0.65 
Event_Sep10 10.42 0.46 1.92 0.95 10.35 0.83 6.86 0.94 
Event_Sep10_M -10.07 0.22 -19.46 0.30 -11.65 0.70 -17.98 0.75 
Event_Nov10 5.02 0.62 36.33 0.12 32.33 0.39 101.00 0.14 
Event_Nov10_M -2.20 0.79 -19.17 0.34 -33.41 0.31 -69.88 0.24 
Event_Feb11 -11.24 0.21 -22.00 0.33 55.50 0.13 -41.50 0.54 
Event_Feb11_M 19.17 <.01 55.50 <.01 52.50 0.01 149.00 <.01 
Event_May11 -5.53 0.22 -10.65 0.43 -6.89 0.76 -28.52 0.48 
Event_May11_M -11.46 <0.01 -26.72 <.01 -13.90 0.34 -70.28 0.01 
Event_Jul12 -0.10 0.98 7.90 0.56 0.11 1.00 16.98 0.67 
Event_Jul12_M -0.03 0.97 -1.76 0.58 -0.10 0.98 -3.34 0.72 
         
AIC 366.7  481.4  539.1  610.6  
SBC 406.2  518.8  576.5  648.0  
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Table VI: Total Contraindicated and Non-Contraindicated Use (Parsimonious Model) 
Parsimonious 
Total Model 
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-
contraindicated 
rosiglitazone 
Non-
contraindicated 
pioglitazone 
  Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept 9.77 <.0001 18.39 0.00 32.21 0.02 59.77 0.01 
AR1,1 -0.36 0.01            
Month -0.51 <.0001 -0.87 0.00 -4.53 0.00 -7.58 0.01 
Event_Dec08_M        4.89 0.01 8.71 0.01 
Event_May10 -13.20 0.01            
Event_May10_M 5.00 0.01 4.84 0.00         
Event_Sep10 13.71 0.01            
Event_Sep10_M -11.04 <.0001            
Event_Nov10            98.05 0.06 
Event_Nov10_M     -26.02 <.0001 -24.79 <.0001 -84.78 0.00 
Event_Feb11_M 12.93 <.0001 37.79 <.0001 77.29 <.0001 133.42 <.0001 
Event_May11_M -6.40 <.0001 -15.99 <.0001 24.76 <.0001 -50.66 <.0001 
         
AIC 356.0  468.0  524.1  591.9   
SBC 374.7   480.5   536.6   606.5   
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Figure VII: Plot of Total Contraindicated and Non-Contraindicated TZD Use 
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Figure VIII: Plot of Total Contraindicated and Non-Contraindicated TZD Use as a Proportion of T2DM Patients 
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Total Contraindicated and Non-Contraindicated Use (Cohort Fixed in First 4 Months of 
Analysis Period) 
All models tested in the restricted sample of eligible patients identified in the first four 
months of the analysis period required one order of differencing to de-trend the data and achieve 
white-noise. No autoregressive or moving average parameters to account for random shocks 
were needed to be modeled. The significant parameters, values and patterns observed for each of 
the 4 full models (Table VII): (1) contraindicated rosiglitazone utilization, (2) non-
contraindicated rosiglitazone utilization, (3) contraindicated pioglitazone utilization, and (4) non-
contraindicated pioglitazone utilization were nearly identical. When reviewing the parsimonious 
model, which was obtained by the stepwise elimination of non-significant coefficients, some 
additional parameters were observed to have a significant impact (Table VIII). Specifically, the 
immediate (decrease) and month-to-month (increase) impact on contraindicated rosiglitazone use 
and the month-to-month (increase) impact on contraindicated pioglitazone use of the May 2010 
event (new meta-analysis published). However, these events had no meaningful impact on the 
overall declining trends in contraindicated and non-contraindicated TZD use (Figure IX). In fact, 
from an observational standpoint (Figure IX and Figure X), the proportion of contraindicated 
patients in the total and restricted sample tracked together very closely indicating not many new 
contraindicated patients were added over the analysis period. 
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Table VII: Total Contraindicated and Non-Contraindicated TZD Use (Full Model) 
Cohort Fixed in First 4 Months of Analysis Period 
Total Model – 
Fixed Cohort in 
First 4 Months 
  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept 14.88 <0.01 28.92 <0.01 41.24 0.01 71.48 0.01 
Month -1.41 0.02 -2.79 0.01 -7.18 < 0.01 -11.21 < 0.01 
Event_Dec08 3.27 0.53 9.00 0.35 26.80 0.17 29.27 0.36 
Event_Dec08_M 1.11 0.23 1.67 0.34 6.58 0.06 12.06 0.04 
Event_Sep09 2.80 0.61 7.62 0.45 19.68 0.34 3.04 0.93 
Event_Sep09_M -0.83 0.45 -0.12 0.95 -2.46 0.56 -0.21 0.98 
Event_May10 -8.16 0.28 -12.14 0.39 -14.00 0.63 -17.94 0.71 
Event_May10_M 4.54 0.08 9.48 0.05 10.36 0.29 4.80 0.77 
Event_Sep10 6.58 0.62 3.12 0.90 8.53 0.86 9.68 0.91 
Event_Sep10_M -4.28 0.60 -17.68 0.25 -12.62 0.68 -5.81 0.91 
Event_Nov10 -2.67 0.79 28.67 0.13 26.33 0.49 64.00 0.31 
Event_Nov10_M -4.63 0.59 -13.06 0.42 -24.68 0.45 -61.63 0.26 
Event_Feb11 -9.83 0.32 -22.83 0.21 44.00 0.23 -25.67 0.67 
Event_Feb11_M 15.00 0.01 46.50 <.01 40.50 0.05 114.00 < 0.01 
Event_May11 -3.59 0.54 -12.32 0.26 -4.80 0.83 -18.12 0.62 
Event_May11_M -9.50 0.02 -24.10 < 0.01 -10.45 0.48 -52.38 0.03 
Event_Jul12 0.06 0.99 4.74 0.66 0.23 0.99 11.11 0.76 
Event_Jul12_M 0.00 1.00 -1.16 0.65 -0.05 0.99 -2.91 0.73 
         
AIC 366.7  456.7  539.9  599.1   
SBC 406.2   494.1   577.3   636.5   
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Table VIII: Total Contraindicated and Non-Contraindicated Use (Parsimonious Model) 
Cohort Fixed in First 4 Months of Analysis Period 
Total Model – 
Fixed Cohort in 
First 4 Months 
  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept 9.27 <.01 27.44 <.01 29.60 0.03 58.89 0.01 
Month -0.50 <.01 -2.47 <.01 -4.68 <.01 -8.51 <.01 
Event_Dec08_M     2.54 0.01 5.34 0.01 10.37 <.01 
Event_Sep10 20.07 <.01            
Event_Sep10_M -5.51 <.01            
Event_Nov10     30.38 0.05         
Event_Nov10_M     -25.32 <.01 -19.94 0.00 -39.92 <.01 
Event_Feb11_M 11.63 <.01 39.66 <.01 19.52 0.00 73.04 <.01 
Event_May11_M -5.64 <.01 -14.63 <.01     -35.51 <.01 
         
AIC 368.7  445.5  524.2  580.5   
SBC 381.2   460.1   536.7   593.0   
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Figure IX: Plot of Total Contraindicated and Non-Contraindicated TZD Use  
Cohort Fixed in First 4 Months of Analysis Period  
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Figure X: Plot of Total Contraindicated and Non-Contraindicated TZD Use as a Proportion of T2DM Patients 
Cohort Fixed in First 4 Months of Analysis Period 
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5
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New Contraindicated and Non-Contraindicated Use (Total Sample) 
Contraindicated rosiglitazone use:  
The new contraindicated rosiglitazone use model required one order of differencing to 
de-trend the data but did not require an autoregressive or moving average parameter. The full 
model (Table IX) had no significant parameter for any intervention. A parsimonious model 
(Table X) was fitted by the step-wise removal of non-significant parameters to obtain a 
statistically better model as measured by AIC and BIC. This model had a significant intercept, 
month-to-month change prior to the intervention, and a small decrease in month-to-month 
utilization following REMS for rosiglitazone. However, these events had a negligible impact on 
new contraindicated rosiglitazone use which was already observed to be less than 10 patients or 
less than 0.05% of all T2DM patients at any point during the observation period (Figure XI and 
Figure XII). 
 
Non-Contraindicated rosiglitazone use:  
The new non-contraindicated rosiglitazone use model required one order of differencing 
to de-trend the data but did not require an autoregressive or moving average parameter. The full 
model (Table IX) had a significant intercept, month-to-month parameter prior to the intervention, 
and a significant month-to-month decline in non-contraindicated rosiglitazone use following the 
December 2008 rosiglitazone REMS intervention. A parsimonious model (Table X) was fitted 
by the step-wise removal of non-significant parameters to obtain a statistically better model as 
measured by AIC and BIC. Similar to the full model, the parsimonious model had a significant 
intercept, month-to-month change prior to the intervention, and a large immediate (coefficient = 
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-64.61, p = 0.02) and month-to-month (coefficient = -26.0, p < 0.01) decline in new non-
contraindicated rosiglitazone utilization following the December 2008 REMS for rosiglitazone. 
This suggests that REMS for contraindicated rosiglitazone may have the unintended effect of 
decreasing all rosiglitazone use, including appropriate use. The change in trend in terms of the 
number of new patients and the proportion of all T2DM patients may be noted in Figure XI and 
Figure XII. 
 
Contraindicated pioglitazone use:  
The new contraindicated pioglitazone use model required one order of differencing to de-
trend the data and 3 autoregressive parameters. The full model (Table IX) had a significant 
intercept, month-to-month parameter prior to the intervention, and a significant month-to-month 
decline in contraindicated pioglitazone use following the December 2008 rosiglitazone REMS 
intervention, as well as an immediate and month-to-month decline in contraindicated 
pioglitazone use following the September 2009 pioglitazone REMS intervention. In addition, a 
small immediate but temporary increase in contraindicated pioglitazone use that approached 
significance was observed when rosiglitazone lost its preferred status in MS Medicaid in 
November 2010 (coefficient = 14.68, p = 0.06). A parsimonious model (Table X) was fitted by 
the step-wise removal of non-significant parameters to obtain a statistically better model as 
measured by AIC and BIC. Similar to the full model, the parsimonious model had a significant 
intercept, month-to-month change prior to the intervention, and a significant impact following 
REMS for rosiglitazone (month-to-month) and pioglitazone interventions (immediate and 
month-to-month). Additional future events were observed to have a significant, but not a 
60 
 
meaningful impact on new contraindicated pioglitazone use due to the overall low use following 
2010 (Figure XI and Figure XII). 
 
Non-Contraindicated pioglitazone use:  
 New non-contraindicated pioglitazone use followed a similar pattern to new non-
contraindicated rosiglitazone use. The new non-contraindicated pioglitazone use model required 
one order of differencing to de-trend the data but did not require an autoregressive or moving 
average parameter. The full model (Table IX) had a significant intercept, month-to-month 
parameter prior to the intervention, and a significant month-to-month decline in non-
contraindicated pioglitazone use (coefficient = -39.22, p < 0.01) following the December 2008 
rosiglitazone REMS intervention. However, the absolute decline in non-contraindicated 
pioglitazone use was larger than in non-contraindicated rosiglitazone. A parsimonious model 
(Table X) was fitted by the step-wise removal of non-significant parameters to obtain a 
statistically better model as measured by AIC and BIC. Similar to the full model, the 
parsimonious model had a significant intercept (coefficient = -337.36, p < 0.001), month-to-
month change prior to the intervention, and a large immediate (coefficient = -99.9, p = 0.01) and 
month-to-month (coefficient = -39.61, p < 0.01) decline in new non-contraindicated pioglitazone 
utilization following the December 2008 REMS for rosiglitazone. This suggests that REMS may 
have the unintended effect of significantly decreasing pioglitazone use, especially appropriate 
use of pioglitazone. The change in trend in terms of the number of new patients and the 
proportion of all T2DM patients may be noted in Figure XI and Figure XII. 
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Table IX: New Contraindicated and Non-Contraindicated TZD Use (Full Model) 
Total Model –  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept -2.62 0.12 -4.15 < 0.001 -222.56 < 0.001 -337.36 < 0.001 
AR1,1     -1.11 < 0.001         
AR1,2     -0.95 < 0.001         
AR1,3     -0.60 < 0.001         
Month 0.22 0.35 0.45 < 0.001 26.02 < 0.001 39.62 < 0.001 
Event_Dec08 1.44 0.47 -0.31 0.75 -64.38 0.15 -101.84 0.10 
Event_Dec08_M -0.42 0.25 -0.48 < 0.01 -25.96 < 0.01 -39.22 < 0.01 
Event_Sep09 0.29 0.89 -2.33 0.03 -1.22 0.98 -5.55 0.93 
Event_Sep09_M 0.24 0.58 0.45 0.02 -0.03 1.00 0.64 0.96 
Event_May10 0.21 0.94 -3.01 0.32 4.03 0.95 -7.42 0.94 
Event_May10_M -0.28 0.78 0.57 0.59 -1.92 0.93 0.65 0.98 
Event_Sep10 0.03 1.00 0.75 0.95 3.08 0.98 -3.64 0.98 
Event_Sep10_M 0.62 0.84 -5.11 0.43 4.11 0.95 -1.52 0.99 
Event_Nov10 0.00 1.00 14.68 0.06 -8.67 0.92 14.00 0.91 
Event_Nov10_M -0.37 0.91 -0.78 0.92 -0.22 1.00 -7.16 0.95 
Event_Feb11 0.00 1.00 1.17 0.87 0.67 0.99 -0.67 1.00 
Event_Feb11_M 0.00 1.00 7.44 <0.01 -2.50 0.96 10.00 0.88 
Event_May11 0.00 1.00 -4.96 0.03 0.50 0.99 -2.75 0.97 
Event_May11_M 0.00 1.00 -2.43 0.27 0.50 0.99 -2.84 0.95 
Event_Jul12 0.00 1.00 -0.29 0.82 0.00 1.00 1.04 0.99 
Event_Jul12_M 0.00 1.00 -0.15 0.65 0.00 1.00 -0.50 0.98 
         
AIC 271.1  302.1  639.7  678.0   
SBC 308.5   345.8   677.1   715.4   
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Table X: New Contraindicated and Non-Contraindicated Use (Parsimonious Model) 
Total Model  
  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept -2.78 0.03 -4.10 < 0.001 -222.56 < 0.001 -337.36 < 0.001 
AR1,1     -1.07 < 0.001        
AR1,2     -0.86 < 0.001        
AR1,3     -0.53 < 0.001        
Month 0.25 0.06 0.44 < 0.001 26.02 < 0.001 39.62 < 0.001 
Event_Dec08        -64.61 0.02 -99.90 0.01 
Event_Dec08_M -0.25 0.07 -0.52 < 0.01 -26.00 < 0.001 -39.61 < 0.001 
Event_Sep09     -1.51 0.06         
Event_Sep09_M     0.32 < 0.01         
Event_Sep10_M     -2.80 < 0.01         
Event_Nov10     8.07 0.04         
Event_Feb11_M     4.53 < 0.01         
Event_May11_M     -3.62 < 0.01         
         
AIC 242.4  292.1  611.8  650.0   
SBC 248.6   319.1   620.1   658.4   
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Figure XI: Plot of New Contraindicated and Non-Contraindicated TZD Use 
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Figure XII: Plot of New Contraindicated and Non-Contraindicated TZD Use as a Proportion of T2DM Patients 
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New Contraindicated and Non-Contraindicated Use (Cohort Fixed in First 4 Months of 
Analysis Period) 
The new TZD use models tested in the restricted sample of eligible patients identified in 
the first four months of the analysis period required one order of differencing to de-trend the data 
and achieve white-noise. In comparison with the total sample, the restricted sample for new 
rosiglitazone contraindicated use has 1 significant autoregressive parameter and the restricted 
sample for new non-contraindicated pioglitazone use has 4 autoregressive parameters. Similar to 
the total sample, the new non-contraindicated rosiglitazone use model required no autoregressive 
or moving average parameters and the contraindicated pioglitazone use model required 4 
autoregressive parameters.  
The significant values and patterns observed for each of the 4 full models (Table XI): (1) 
contraindicated rosiglitazone utilization, (2) non-contraindicated rosiglitazone utilization, (3) 
contraindicated pioglitazone utilization, and (4) non-contraindicated pioglitazone utilization were 
nearly identical. However, in comparison, the month-to-month parameter before any intervention 
and after the December 2008 REMS for new contraindicated rosiglitazone use became 
significant in the restricted model, while the pioglitazone co-efficient became non-significant in 
the new contraindicated pioglitazone model. Similar patterns were observed in the parsimonious 
model, which was obtained by the step-by-step elimination of non-significant coefficients (Table 
XII). These events had no meaningful impact on the overall declining trends in new 
contraindicated TZD use (Figure XIII). However, the impact on the decline in new non-
contraindicated rosiglitazone (immediate- coefficient = -65.2; p = 0.02 and month-to-month- 
coefficient = -26.4, p < 0.001) and new non-contraindicated pioglitazone (immediate- coefficient 
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= -58.85, p < 0.01) use was large even in the restricted sample following the REMS for 
rosiglitazone (December 2008). 
 
Table XI: New Contraindicated and Non-Contraindicated TZD Use (Full Model) 
Cohort Fixed in First 4 Months of Analysis Period 
Total Model –  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept -3.77 < 0.001 -4.67 < 0.001 -226.02 < 0.001 -777.39 < 0.01 
AR1,1 -0.42 < 0.01 -1.24 < 0.001     2.20 < 0.001 
AR1,2     -1.06 < 0.001     -2.64 < 0.001 
AR1,3     -0.66 < 0.001     1.90 < 0.001 
AR1,4            -0.81 < 0.001 
Month -0.49 0.68 -0.68 0.24 -66.08 0.14 36.63 0.19 
Event_Dec08 -0.45 0.02 -0.51 < 0.001 -26.18 < 0.01 -112.11 0.01 
Event_Dec08_M -0.05 0.97 -0.48 0.46 -1.99 0.97 -8.33 0.73 
Event_Sep09 0.10 0.69 0.12 0.28 -0.09 0.99 38.90 0.26 
Event_Sep09_M 1.83 0.35 -1.47 0.42 0.91 0.99 12.39 0.69 
Event_May10 -0.95 0.14 0.64 0.32 -0.49 0.98 -15.75 0.77 
Event_May10_M 0.74 0.87 0.17 0.98 0.37 1.00 -1.38 0.97 
Event_Sep10 1.29 0.63 -3.00 0.48 0.52 0.99 -4.11 0.95 
Event_Sep10_M 0.12 0.97 5.64 0.28 -1.33 0.99 0.70 0.99 
Event_Nov10 -0.41 0.88 0.48 0.92 0.32 1.00 8.15 0.94 
Event_Nov10_M 0.01 1.00 2.41 0.61 -0.17 1.00 -20.56 0.73 
Event_Feb11 0.01 0.99 1.80 0.22 -0.50 0.99 5.49 0.96 
Event_Feb11_M 0.00 1.00 -0.96 0.48 0.00 1.00 23.06 0.44 
Event_May11 0.00 1.00 0.05 0.97 0.00 1.00 -6.02 0.92 
Event_May11_M 0.00 1.00 -0.34 0.66 0.00 1.00 7.80 0.76 
Event_Jul12 0.00 1.00 -0.01 0.97 0.00 1.00 -0.81 0.98 
Event_Jul12_M -3.77 < 0.001 -4.67 < 0.001 -226.02 < 0.001 -777.39 < 0.01 
         
AIC 237.5  250.6  638.4  627.3   
SBC 277.0   294.2   675.8   673.0   
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Table XII: New Contraindicated and Non-Contraindicated Use (Parsimonious Model) 
Cohort Fixed in First 4 Months of Analysis Period 
Total Model  
  
Contraindicated 
rosiglitazone 
Contraindicated 
pioglitazone 
Non-contraindicated 
rosiglitazone 
Non-contraindicated 
pioglitazone 
Co-eff p-value Co-eff p-value Co-eff p-value Co-eff p-value 
Intercept -3.28 < 0.001 -4.80 < 0.001 -226.02 < 0.001 -601.18 < 0.01 
AR1,1 -0.36 < 0.01 -1.16 < 0.001     2.28 < 0.001 
AR1,2     -0.91 < 0.001     -2.74 < 0.001 
AR1,3     -0.55 < 0.001     1.84 < 0.001 
AR1,4            -0.70 < 0.001 
Month 0.31 < 0.001 0.51 <.0001 26.42 < 0.001 57.77 < 0.01 
Event_Dec08     -1.01 0.02 -65.20 0.02 -58.85 < 0.01 
Event_Dec08_M -0.31 < 0.01 -0.49 <.0001 -26.40 < 0.001     
Event_Sep10_M     -0.18 0.01         
Event_Feb11_M     0.20 < 0.01         
         
AIC 212.8  240.1  610.4  606.9   
SBC 221.1   258.8   618.7   621.5   
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Figure XIII: Plot of New Contraindicated and Non-Contraindicated TZD Use 
Cohort Fixed in First 4 Months of Analysis Period
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Figure XIV: Plot of New Contraindicated and Non-Contraindicated TZD Use as a Proportion of T2DM Patients 
Cohort Fixed in First 4 Months of Analysis Period
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V. DISCUSSION AND IMPLICATIONS 
 
 This research examined the trends and effect of multiple safety events on the 
contraindicated utilization of rosiglitazone and pioglitazone, and any potential effects on the 
appropriate use of both rosiglitazone and pioglitazone. The observation period for this study was 
4 years or 48 months, beginning in January 2008 through December 2012. The key interventions 
studied during this period were the effectives of medication guide REMS programs for 
rosiglitazone in December 2008 (month 12 of the study observation period) and pioglitazone in 
September 2009 (month 21). The analysis approach accounted for any autocorrelations and 
random shocks existing in the data that may bias the interpretation and may potentially increase 
interpretation error by using an ARIMA model.  
Analysis of the trends and modeling the data revealed, not only, a lasting effect of safety 
warnings that occurred prior to analysis period (2007) on contraindicated rosiglitazone use, but 
also a notable effect on overall TZD use. Specifically, both contraindicated and non-
contraindicated rosiglitazone and pioglitazone use was observed to be on a sharp downward 
trend at the beginning of the analysis period in 2008, most likely on account of the initial safety 
warnings (black box warnings) issued in May 2007 by the FDA for rosiglitazone. The 
blockbuster status of TZD’s resulted in extensive attention for rosiglitazone in the scientific, 
regulatory and medical communities, and the media following the research that led up to the May 
2007 safety warnings. These effects cumulatively had a pronounced and lasting effect on all 
TZD use and succeeding interventions only had an added, yet subdued, effect on this declining
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TZD use. Oko-Osi et al.86 examined TZD use in a Medicare population between 2006 and 2008. 
They observed a sharp and consistent decline for overall rosiglitazone use (contraindicated, at 
risk and appropriate use) amounting to a 75-90% decline and contraindicated pioglitazone use 
following the initial May 2007 safety warnings, but a flat trend in at-risk and appropriate 
pioglitazone use. Contrary to the findings of Oko-Osi et al.87, this study revealed an existing and 
lasting overall decline in TZD use from the start of the analysis period. The targeted effect of 
safety interventions were not borne out in the data. However, it is quite possible, that if Oko-Osi 
et al. extended their analysis timeframe beyond 2008 they would have observed a similar 
downward trend in total TZD use. 
While the interventions had minimal impact on the already declining contraindicated 
TZD use, a key finding is the added observed month-to-month decline in non-contraindicated 
TZD use. The negative co-efficient for non-contraindicated use in the models signify that the 
total number of non-contraindicated rosiglitazone and pioglitazone users (Table VI) declined by 
5 and 8 respectively each month following the REMS for rosiglitazone intervention in December 
2008. However, the intervention had a more pronounced month-to-month decline in new non-
contraindicated use, with 65 and 100 fewer rosiglitazone and pioglitazone patients (Table X) 
added each month. This finding is possibly the most important finding from the research that 
deserves to be considered when developing REMS and safe use programs. The current medical 
environment appears to be risk-averse to the use of drugs that have some safety concerns 
associated with them and will discontinue use of the product even in patients who may actually 
benefit from them. The media and regulatory attention accorded to safety programs for specific 
drugs may result in its effects being broader than planned. The importance of any new safety 
information being appropriately tempered until adequate research is available is apparent given 
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that the FDA, 88 in 2013, lifted all restrictions and warnings against TZDs after further post-
market data and trials demonstrated no significant negative impact on patient safety outcomes. 
However, at this point TZD use was almost non-existent for the management of diabetes. 
Another metric demonstrating the impact on overall TZD utilization is the almost non-
existent new TZD use over the analysis period. New TZD use was observed to be at less than 5 
contraindicated rosiglitazone users and less than 10 contraindicated pioglitazone users, each 
month, between 2008 and 2009 and this dropped to almost 0 after rosiglitazone lost its preferred 
status in MS Medicaid. However, new non-contraindicated TZD utilization was also 
dramatically lower at less than 20 rosiglitazone and 50 pioglitazone patients each month, until 
loss of preferred status resulted in use that approached 0. This effect can be confirmed by 
tracking the decline of the total sample of TZD users and TZD use in the restricted sample of 
TZD users, which suggests that new T2DM patients were not put on TZDs irrespective of 
whether they have a contraindicated cardiovascular event as a risk factor.  
In conclusion, while prior studies18, 23, 53, 54 demonstrated a small decline in TZD use 
following the warnings (i.e., over 20% of TZD use still remaining contraindicated in the 2007-
2008 timeframe), this analysis showed that safety concerns and aggressive use mitigation 
strategies have an immediate, pronounced and lasting effect on overall use.  
 
Limitations 
A key limitation of this research is not being able to account for the May 2007 safety 
warnings which clearly appear to have set overall TZD use on a steep downward trajectory. To a 
greater extent, the impact of the accompanying media attention could not be accounted for. 
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These events appear to have a stronger effect on the TZD trajectory as is observable by the 
significant month-to-month parameters prior to interventions included in the models.  
Further, the loss of preferred status in a Medicaid program would result in the automatic 
withdrawal of use despite what physician’s actual use preferences might be. This prevents the 
modeling of informed prescribing behaviors of physicians in the eligible Medicaid population 
difficult. 
Another important consideration is that the generalizability of the results is limited to the 
MS Medicaid eligible population only. Drug use patterns can be uniquely influenced by 
guidelines set forth by the review boards of each state. Interestingly in this study, while the 
declining trend in contraindicated and non-contraindicated use patterns appear consistent with 
that observed by Oko-Osi et al. among Medicare beneficiaries, a much more aggressive decline 
was observed in TZD use, including non-contraindicated use. 
 
Future Research 
 The events surrounding rosiglitazone and pioglitazone use in the 2008-2012 timeframe 
and the May 2007 safety warnings and accompanying media attention created a unique 
environment that may have confounded a clean evaluation of the impact of a REMS program. 
Future research is therefore warranted among a broader range of drugs to test the overall impact 
of REMS, particularly the impact of medication guides.  
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